Therapeutic targeting of oncogenic transforming growth factor-β1 signaling by antisense oligonucleotides in oral squamous cell carcinoma

Oncology Reports
Seong-Gon Kim, Ji-Young Song

Abstract

The transforming growth factor-β1 (TGF-β1) signaling pathway is important in human oral squamous cell carcinoma (OSCC). Accordingly, the aims of this study were to evaluate the effect of antisense TGF-β1 oligonucleotides (ODNs) on OSCC in cell culture and in a xenograft model, as well as to evaluate any effects ODNs have on proliferating cell nuclear antigen (PCNA) and matrix metalloproteinase-2 (MMP-2) expression in the xenograft model. We performed real-time cell electronic sensing (RT-CES) to determine the effect of antisense TGF-β1 ODNs on SCC-9 cell growth. To examine the in vivo effect of antisense TGF-β1 ODN therapy, SCC-9 cells were grafted into nude mice. Antisense ODNs were injected into the mass daily. Tumor size, body weight and duration of survival were assessed daily. Specimens from the main mass were used for immunohistochemical staining to analyze PCNA and MMP-2 expression. In vitro treatment with antisense TGF-β1 ODNs decreased TGF-β1 expression and growth of SCC-9 cells. In the xenograft model, the antisense TGF-β1 ODN group exhibited a significantly decreased tumor growth rate compared to the control, which received Dulbecco's modified Eagle's medium (DMEM) (P=0.022). However, mean survival time and body weig...Continue Reading

References

Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·T M WoolfC G Jennings
Jan 1, 1983·Journal of Cancer Research and Clinical Oncology·G CarlssonL Hafström
Jan 1, 1993·Annual Review of Cell Biology·W G Stetler-StevensonL A Liotta
Jul 27, 1999·The Journal of Biological Chemistry·H Nagase, J F Woessner
Sep 1, 1999·Journal of Pediatric Gastroenterology and Nutrition·P LionettiA Vierucci
Jun 19, 2001·International Journal of Cancer. Journal International Du Cancer·V EllenriederT M Gress
Jan 16, 2002·Current Opinion in Genetics & Development·Lalage M Wakefield, Anita B Roberts
May 1, 2002·Current Opinion in Oncology·Edward S KimRoy S Herbst
Aug 22, 2002·Nature Reviews. Cancer·Jean Paul Thiery
Dec 2, 2004·Nature Reviews. Drug Discovery·Jonathan M YinglingJ Scott Sawyer
Aug 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lakisha D MooreSelvarangan Ponnazhagan
Apr 25, 2009·Molecular Pharmaceutics·Kun ChengRam I Mahato

❮ Previous
Next ❯

Citations

Sep 26, 2013·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Daoguang WangYuxiang Du
Jan 10, 2003·Seminars in Radiation Oncology·Dietmar W Siemann, Wenyin Shi
Jul 15, 2017·International Journal of Molecular Sciences·Ammad Ahmad FarooqiHsueh-Wei Chang
Jun 3, 2017·Human Vaccines & Immunotherapeutics·Sulsal Haque, John C Morris
Sep 13, 2015·Experimental Biology and Medicine·Meirong LiXiaobing Fu
Dec 31, 2018·Molecular Therapy. Nucleic Acids·Bao T LeRakesh N Veedu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.